LU92701I2 - Pasiréotide ou un sel pharmaceutiquement acceptable qui en dérive ou un hydrate qui en dérive - Google Patents

Pasiréotide ou un sel pharmaceutiquement acceptable qui en dérive ou un hydrate qui en dérive Download PDF

Info

Publication number
LU92701I2
LU92701I2 LU92701C LU92701C LU92701I2 LU 92701 I2 LU92701 I2 LU 92701I2 LU 92701 C LU92701 C LU 92701C LU 92701 C LU92701 C LU 92701C LU 92701 I2 LU92701 I2 LU 92701I2
Authority
LU
Luxembourg
Prior art keywords
pasireotide
hydrate
leads
occur
pharmaceutically acceptable
Prior art date
Application number
LU92701C
Other languages
English (en)
French (fr)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34593737&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92701(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0326602A external-priority patent/GB0326602D0/en
Priority claimed from GB0406241A external-priority patent/GB0406241D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of LU92701I2 publication Critical patent/LU92701I2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
LU92701C 2003-11-14 2015-04-29 Pasiréotide ou un sel pharmaceutiquement acceptable qui en dérive ou un hydrate qui en dérive LU92701I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0326602A GB0326602D0 (en) 2003-11-14 2003-11-14 Organic compounds
GB0406241A GB0406241D0 (en) 2004-03-19 2004-03-19 Organic compounds
PCT/EP2004/012870 WO2005046645A1 (en) 2003-11-14 2004-11-12 Microparticles comprising somatostatin analogues

Publications (1)

Publication Number Publication Date
LU92701I2 true LU92701I2 (fr) 2015-11-02

Family

ID=34593737

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92701C LU92701I2 (fr) 2003-11-14 2015-04-29 Pasiréotide ou un sel pharmaceutiquement acceptable qui en dérive ou un hydrate qui en dérive

Country Status (31)

Country Link
US (3) US7759308B2 (no)
EP (1) EP1686964B9 (no)
JP (1) JP4682145B2 (no)
KR (1) KR101233892B1 (no)
AR (1) AR047310A1 (no)
AT (1) ATE455537T1 (no)
AU (1) AU2004289055C1 (no)
BR (1) BRPI0416227B8 (no)
CA (1) CA2541944C (no)
CY (2) CY1110293T1 (no)
DE (1) DE602004025271D1 (no)
DK (1) DK1686964T3 (no)
EC (1) ECSP066565A (no)
ES (1) ES2339026T3 (no)
HK (1) HK1093682A1 (no)
HR (1) HRP20100190T1 (no)
IL (1) IL175286A (no)
IS (1) IS8480A (no)
LU (1) LU92701I2 (no)
MA (1) MA28155A1 (no)
MX (1) MXPA06005357A (no)
MY (1) MY158342A (no)
NO (2) NO337172B1 (no)
NZ (1) NZ546788A (no)
PE (1) PE20050581A1 (no)
PL (1) PL1686964T3 (no)
PT (1) PT1686964E (no)
RU (1) RU2404749C2 (no)
SI (1) SI1686964T1 (no)
TW (1) TWI295178B (no)
WO (1) WO2005046645A1 (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY158342A (en) * 2003-11-14 2016-09-30 Novartis Ag Pharmaceutical composition
PL1968549T3 (pl) * 2005-12-22 2014-10-31 Novartis Ag Preparat o podtrzymywanym uwalnianiu zawierający okterotyd i dwa lub większą liczbę polimerów typu poli(mleczan-co-glikolan)
KR100816065B1 (ko) * 2006-11-27 2008-03-24 동국제약 주식회사 초기 방출억제 특성이 우수한 서방출성 마이크로캡슐의제조방법 및 이에 의해 제조되는 마이크로캡슐
PE20090387A1 (es) * 2007-05-24 2009-04-28 Novartis Ag Formulacion de pasireotida
KR101921800B1 (ko) * 2008-01-30 2018-11-23 노파르티스 아게 옥트레오티드 및 3종의 선형 폴리락티드-코-글리콜리드 중합체를 포함하는 서방형 제제
JP5562324B2 (ja) * 2008-04-03 2014-07-30 ザイモジェネティクス， インコーポレイテッド 止血マイクロスフェア
PL2310042T3 (pl) 2008-07-08 2013-05-31 Novartis Ag Zastosowanie pasyreotydu do leczenia endogennej hipoglikemii hiperinsulinemicznej
US20100151033A1 (en) * 2008-12-15 2010-06-17 Novartis Ag Octreotide depot formulation with constantly high exposure levels
US8822610B2 (en) 2008-12-22 2014-09-02 ATRP Solutions, Inc. Control over controlled radical polymerization processes
US8815971B2 (en) 2008-12-22 2014-08-26 ATRP Solutions, Inc. Control over controlled radical polymerization processes
US8173750B2 (en) 2009-04-23 2012-05-08 ATRP Solutions, Inc. Star macromolecules for personal and home care
US8569421B2 (en) 2009-04-23 2013-10-29 ATRP Solutions, Inc. Star macromolecules for personal and home care
WO2014036498A2 (en) 2012-08-30 2014-03-06 ATRP Solutions, Inc. Dual mechanism thickening agents for hydraulic fracturing fluids
US9783628B2 (en) 2009-04-23 2017-10-10 ATRP Solutions, Inc. Dual-mechanism thickening agents for hydraulic fracturing fluids
US9587064B2 (en) 2010-12-08 2017-03-07 ATRP Solutions, Inc. Salt-tolerant star macromolecules
WO2013131879A1 (en) 2012-03-07 2013-09-12 Novartis Ag New application for pasireotide
CN105263978B (zh) 2013-02-04 2018-04-17 Atrp解决方案公司 耐盐星形大分子
US9737605B2 (en) 2013-03-11 2017-08-22 Durect Corporation Injectable controlled release composition comprising high viscosity liquid carrier
TW201605488A (zh) * 2013-10-15 2016-02-16 大塚製藥股份有限公司 用以預防及／或治療多囊腎病之藥物
MX2017000076A (es) 2014-07-03 2017-05-01 Atrp Solutions Inc Macromoleculas estrellas compatibles con tensoactivos.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU221294B1 (en) 1989-07-07 2002-09-28 Novartis Ag Process for producing retarde compositions containing the active ingredient in a polymeric carrier
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
MY147327A (en) 1995-06-29 2012-11-30 Novartis Ag Somatostatin peptides
AU5678398A (en) * 1997-01-29 1998-08-18 Takeda Chemical Industries Ltd. Sustained-release microspheres, their production and use
EP1240896A3 (en) 1998-07-23 2003-03-26 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Encapsulation of water soluble peptides
WO2000004916A1 (en) * 1998-07-23 2000-02-03 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Encapsulation of water soluble peptides
JP2002521343A (ja) * 1998-07-23 2002-07-16 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス 水溶性ペプチドのカプセル化
EP1204429B1 (en) 1999-08-18 2003-10-29 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Sustained release formulation of a peptide
GB0018891D0 (en) * 2000-08-01 2000-09-20 Novartis Ag Organic compounds
WO2003075892A1 (en) * 2002-03-13 2003-09-18 Novartis Ag Pharmaceutical microparticles
MY158342A (en) * 2003-11-14 2016-09-30 Novartis Ag Pharmaceutical composition

Also Published As

Publication number Publication date
TWI295178B (en) 2008-04-01
RU2006120484A (ru) 2007-12-27
SI1686964T1 (sl) 2010-05-31
PL1686964T3 (pl) 2010-06-30
PT1686964E (pt) 2010-02-04
JP4682145B2 (ja) 2011-05-11
US20120214749A1 (en) 2012-08-23
ATE455537T1 (de) 2010-02-15
CA2541944C (en) 2014-02-25
NO2016003I2 (no) 2016-02-02
TW200529883A (en) 2005-09-16
US8188037B2 (en) 2012-05-29
EP1686964B9 (en) 2010-08-04
NO20062777L (no) 2006-08-14
IS8480A (is) 2006-05-23
WO2005046645A1 (en) 2005-05-26
ES2339026T3 (es) 2010-05-14
KR101233892B1 (ko) 2013-02-18
ECSP066565A (es) 2006-10-17
JP2007511482A (ja) 2007-05-10
EP1686964A1 (en) 2006-08-09
CY2015011I1 (el) 2016-04-13
US20070212418A1 (en) 2007-09-13
BRPI0416227A (pt) 2007-01-02
DE602004025271D1 (de) 2010-03-11
US20100272809A1 (en) 2010-10-28
CA2541944A1 (en) 2005-05-26
MY158342A (en) 2016-09-30
IL175286A0 (en) 2006-09-05
NO337172B1 (no) 2016-02-01
MA28155A1 (fr) 2006-09-01
KR20060115873A (ko) 2006-11-10
AU2004289055B2 (en) 2008-10-30
RU2404749C2 (ru) 2010-11-27
AU2004289055A1 (en) 2005-05-26
HRP20100190T1 (hr) 2010-06-30
NZ546788A (en) 2009-12-24
PE20050581A1 (es) 2005-09-09
NO2016003I1 (no) 2016-02-02
CY1110293T1 (el) 2015-01-14
BRPI0416227B1 (pt) 2019-06-18
AR047310A1 (es) 2006-01-18
EP1686964B1 (en) 2010-01-20
IL175286A (en) 2012-05-31
BRPI0416227B8 (pt) 2021-05-25
DK1686964T3 (da) 2010-05-17
CY2015011I2 (el) 2016-04-13
HK1093682A1 (en) 2007-03-09
US7759308B2 (en) 2010-07-20
MXPA06005357A (es) 2006-07-10
AU2004289055C1 (en) 2009-05-21

Similar Documents

Publication Publication Date Title
LU92701I2 (fr) Pasiréotide ou un sel pharmaceutiquement acceptable qui en dérive ou un hydrate qui en dérive
LU92684I2 (fr) Fidaxomicine ou son sel pharmaceutiquement acceptable
LU92702I2 (fr) Naloxegol ou un sel pharmaceutiquement acceptable de celui-ci (moventig)
LU92883I2 (fr) Sonidégib ou un sel, hydrate ou solvate pharmaceutiquement acceptable qui en dérive
LU92678I2 (fr) Tobramycine ou un sel pharmaceutiquement acceptable qui en dérive
NO2013008I2 (no) Krizotinib eller et farmasøytisk akseptabelt salt, hydrat eller solvat derav
DK1704324T3 (da) Leddelt falsk havbund
DE50307359D1 (de) Mehrdecksiebmaschine
DE60317391D1 (de) Verbinder
SE0203705L (sv) Vinkelhake
DE60335913D1 (de) Ghrelin-analoga
DE60301239D1 (de) Verbinder
NO20042118L (no) Halvt neddykkbar offshoreplattform
DE60208885D1 (de) Verbinder
DE60315937D1 (de) Verbinder
NO20020265L (no) Fortöyningsanordning
AP2004003156A0 (en) Peptide deformylase inhibitors.
DE60330377D1 (de) Giessgefäss
DE60223352D1 (de) Verbinder
ITMI20022022A1 (it) Analoghi di nocicettina.
DE10301279B8 (de) Verbinder
DE60218623D1 (de) Verbinder
ITTO20020045A0 (it) Giubbotto per immersione.
DE60312105D1 (de) Verbinder
NO20021944D0 (no) Fartöy